- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02076685
NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis
March 13, 2014 updated by: National Taiwan University Hospital
The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis
To improve the treatment outcome in patients with tuberculosis and integrate the pharmacogenetics into clinical practice, the information of NAT2 genotyping was used in re-challenge protocol for isoniazid (INH) titration in patients with anti-tuberculosis medication-induced hepatitis.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Li-Jiuan Shen, Ph.D.
- Email: ljshen@ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Li-Jiuan Shen, Ph.D.
- Email: ljshen@ntu.edu.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- >= 18 years.
- Take INH for at least a week.
- abnormal liver function (ALT (alanine, transaminase) increased by more than three times the upper limit of normal, or ALT higher than twice the upper limit of normal and total bilirubin higher than 2.0 mg / dL
Exclusion Criteria:
1.Taking INH before liver function abnormalities. 2.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: isoniazid rechalleng
When patients encountered hepatotoxicity during the anti-TB treatment, genotyping and pk study of INH would be performed and dose adjustment accordingly.
|
dose adjustment according to the pharmacogenomic results
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
successful re-use of isoniazid for TB treatment
Time Frame: 6 months
|
In this study, we would like to test the hypothesis of NAT2 genotyping helping in isoniazid rechallenge after patients experienced adverse effects of anti-TB treatment.
Therefore, to observe the patients can re-use isoniazid successfully is an important outcome measure in this study.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shen Li Jiuan, Ph.D, Nationa Taiwan University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2007
Primary Completion (Anticipated)
November 1, 2015
Study Completion (Anticipated)
November 1, 2015
Study Registration Dates
First Submitted
November 16, 2012
First Submitted That Met QC Criteria
February 26, 2014
First Posted (Estimate)
March 3, 2014
Study Record Updates
Last Update Posted (Estimate)
March 17, 2014
Last Update Submitted That Met QC Criteria
March 13, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 200805015M
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatotoxicity
-
Fundación Pública Andaluza para la Investigación...Not yet recruitingPrednisone | Hepatotoxicity | Idiosyncratic Drug Effect
-
Dr. Marco L.A. SivilottiCompleted
-
Tufts UniversityNational Institute of General Medical Sciences (NIGMS)CompletedPain | Fever | HepatotoxicityUnited States
-
Groupe Hospitalier Pitie-SalpetriereCompletedLiver Diseases | Liver Failure | Liver Dysfunction | HepatotoxicityFrance
-
University Hospital, GenevaUnknownMalnutrition | Paracetamol Toxicity | HepatotoxicitySwitzerland
-
All India Institute of Medical Sciences, New DelhiCompletedTuberculosis | Drug Induced HepatotoxicityIndia
-
National Taiwan University HospitalDepartment of Health, Executive Yuan, R.O.C. (Taiwan)Unknown
-
Children's Hospital of Orange CountyUniversity of California, IrvineRecruitingAcute Lymphoblastic Leukemia | HepatotoxicityUnited States
-
Daiichi Sankyo, Inc.RecruitingTenosynovial Giant Cell Tumor | HepatotoxicityUnited States
Clinical Trials on isoniazid
-
Instituto Nacional de Salud Publica, MexicoWithdrawnDiabetes Mellitus | Latent Tuberculosis
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Federal University... and other collaboratorsRecruitingTuberculosis Infection | Isoniazid Adverse ReactionBrazil
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | TuberculosisHaiti, South Africa, Thailand, Tanzania, Botswana, Zimbabwe, India, Uganda
-
Hospital Universitari de BellvitgeCellestisCompletedLatent Tuberculosis InfectionSpain
-
National Taiwan University HospitalUnknownLatent Tuberculosis InfectionTaiwan
-
National Institute on Drug Abuse (NIDA)Johns Hopkins UniversityUnknown
-
University of Cape TownLondon School of Hygiene and Tropical Medicine; Johns Hopkins University; Imperial... and other collaboratorsCompletedHIV Infections | Tuberculosis | Latent Tuberculosis InfectionSouth Africa
-
Asan Medical CenterCompleted
-
University of CologneTerminatedPulmonary TuberculosisGermany, Bulgaria, Poland
-
Pharma 2100WithdrawnArterial Leg UlcerDenmark